001     274230
005     20240229154929.0
024 7 _ |a 10.1002/smtd.202201605
|2 doi
024 7 _ |a pmid:36908010
|2 pmid
024 7 _ |a altmetric:144442985
|2 altmetric
037 _ _ |a DKFZ-2023-00516
041 _ _ |a English
082 _ _ |a 620
100 1 _ |a Mircetic, Jovan
|0 P:(DE-He78)5f4f1502f9cd9f89b1f6d14d76c68bee
|b 0
|u dkfz
245 _ _ |a CRISPR/Cas9 Screen in Gastric Cancer Patient-Derived Organoids Reveals KDM1A-NDRG1 Axis as a Targetable Vulnerability.
260 _ _ |a Weinheim
|c 2023
|b WILEY-VCH Verlag GmbH & Co. KGaA
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1687854661_19593
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2023 Jun;7(6):e2201605
520 _ _ |a Viability CRISPR screens have proven indispensable in parsing genome function. However, their application in new, more physiologically relevant culturing systems like patient-derived organoids (PDOs) has been much slower. To probe epigenetic contribution to gastric cancer (GC), the third leading cause of cancer-related deaths worldwide, the first negative selection CRISPR screen in GC PDOs that faithfully preserve primary tumor characteristics is performed. Extensive quality control measurements showing feasibility of CRISPR screens in primary organoid culture are provided. The screen reveals the histone lysine demethylase-1A (KDM1A) to constitute a GC vulnerability. Both genetic and pharmacological inhibition of KDM1A cause organoid growth retardation. Further, it is shown that most of KDM1A cancer-supporting functions center on repression of N-myc downstream regulates gene-1 (NDRG1). De-repression of NDRG1 by KDM1A inhibitors (KDM1Ai) causes inhibition of Wnt signaling and a strong G1 cell cycle arrest. Finally, by profiling 20 GC PDOs, it is shown that NDRG1 upregulation predicts KDM1Ai response with 100% sensitivity and 82% specificity in the tested cohort. Thus, this work pioneers the use of negative selection CRISPR screens in patient-derived organoids, identifies a marker of KDM1Ai response, and accordingly a cohort of patients who may benefit from such therapy.
536 _ _ |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312)
|0 G:(DE-HGF)POF4-312
|c POF4-312
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a CRISPR screen
|2 Other
650 _ 7 |a KDM1A-NDRG1 axis
|2 Other
650 _ 7 |a epigenetic regulators
|2 Other
650 _ 7 |a gastric cancer
|2 Other
650 _ 7 |a patient-derived organoids
|2 Other
700 1 _ |a Camgöz, Aylin
|0 P:(DE-He78)dd60ad1c45db7fcacc5be5238ad17e7d
|b 1
|u dkfz
700 1 _ |a Abohawya, Moustafa
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Ding, Li
|b 3
700 1 _ |a Dietzel, Julia
|b 4
700 1 _ |a Tobar, Sebastián García
|b 5
700 1 _ |a Paszkowski-Rogacz, Maciej
|b 6
700 1 _ |a Seidlitz, Therese
|b 7
700 1 _ |a Schmäche, Tim
|b 8
700 1 _ |a Mehnert, Marie-Christin
|b 9
700 1 _ |a Sidorova, Olga
|b 10
700 1 _ |a Weitz, Jürgen
|b 11
700 1 _ |a Buchholz, Frank
|0 0000-0002-4577-3344
|b 12
700 1 _ |a Stange, Daniel E
|0 P:(DE-HGF)0
|b 13
773 _ _ |a 10.1002/smtd.202201605
|g p. 2201605 -
|0 PERI:(DE-600)2884448-8
|n 6
|p e2201605
|t Small Methods
|v 7
|y 2023
|x 2366-9608
909 C O |p VDB
|o oai:inrepo02.dkfz.de:274230
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)5f4f1502f9cd9f89b1f6d14d76c68bee
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)dd60ad1c45db7fcacc5be5238ad17e7d
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 13
|6 P:(DE-HGF)0
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-312
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Funktionelle und strukturelle Genomforschung
|x 0
914 1 _ |y 2023
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2022-11-12
|w ger
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2022-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2022-11-12
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b SMALL METHODS : 2022
|d 2023-08-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-08-22
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-08-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1150
|2 StatID
|b Current Contents - Physical, Chemical and Earth Sciences
|d 2023-08-22
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b SMALL METHODS : 2022
|d 2023-08-22
920 1 _ |0 I:(DE-He78)DD01-20160331
|k DD01
|l DKTK Koordinierungsstelle Dresden
|x 0
920 1 _ |0 I:(DE-He78)B062-20160331
|k B062
|l B062 Pädiatrische Neuroonkologie
|x 1
920 1 _ |0 I:(DE-He78)HD01-20160331
|k HD01
|l DKTK HD zentral
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)DD01-20160331
980 _ _ |a I:(DE-He78)B062-20160331
980 _ _ |a I:(DE-He78)HD01-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21